The investigation of the renal protective effect of Carperitide(hANP:human atrial natriuretic peptide) during adult living donor renal transplantation, a single center experience.

The investigation of the renal protective effect of Carperitide(hANP:human atrial natriuretic peptide) during adult living donor renal transplantation, a single center experience. - The investigation of renal protective effect of Carperitide during adult living donor renal transplantation.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014279

Enrollment

Registered

2014-06-16

Start date

2008-07-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

living donor renal transplantation

Interventions

After the induction of general anesthesia, Carperitide or placebo drug(normal saline) was intravenously administrated at a rate of 0.025mcg/kg/min. We measured urinary liver-type fatty acid binding pr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with written informed consent

Exclusion criteria

Exclusion criteria: Patients without written informed consent

Design outcomes

Primary

Measure	Time frame
The concentrations of urinary liver-type fatty acid binding protein after renal transplantation.	—

Countries

Japan

Contacts

Public ContactRikizo Kogawa

Toho University School of Medicine Department of Anesthesiology

rikizo.kogawa@med.toho-u.ac.jp03-3762-4151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026